BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 20230219)

  • 1. Clonogenic assays measure leukemia stem cell killing not detectable by chromium release and flow cytometric cytotoxicity assays.
    Williams BA; Wang XH; Keating A
    Cytotherapy; 2010 Nov; 12(7):951-60. PubMed ID: 20230219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model.
    Swift BE; Williams BA; Kosaka Y; Wang XH; Medin JA; Viswanathan S; Martinez-Lopez J; Keating A
    Haematologica; 2012 Jul; 97(7):1020-8. PubMed ID: 22271890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flow cytometry-based assay for determination of teleost cytotoxic cell lysis of target cells.
    Oumouna M; Jaso-Friedmann L; Evans DL
    Cytometry; 2001 Dec; 45(4):259-66. PubMed ID: 11746095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An improved flow cytometry-based natural killer cytotoxicity assay involving calcein AM staining of effector cells.
    Jang YY; Cho D; Kim SK; Shin DJ; Park MH; Lee JJ; Shin MG; Shin JH; Suh SP; Ryang DW
    Ann Clin Lab Sci; 2012; 42(1):42-9. PubMed ID: 22371909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance of leukemic stem-like cells in AML cell line KG1a to natural killer cell-mediated cytotoxicity.
    She M; Niu X; Chen X; Li J; Zhou M; He Y; Le Y; Guo K
    Cancer Lett; 2012 May; 318(2):173-9. PubMed ID: 22198207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antileukemia activity of a natural killer cell line against human leukemias.
    Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
    Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between clonogenic and cytotoxic assays for measuring LAK cell activity.
    Kluin-Nelemans HC; van der Harst D; van den Burgh JF; van Luxemburg S; Brand A
    Int J Cell Cloning; 1989 Jul; 7(4):232-41. PubMed ID: 2768841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cytotoxicity of allogenetic natural killer cells against CD34+ acute myelogenous leukemia cells].
    Niu XQ; Guo KY; Zhou J; Hu LS; Tu SF; She MR
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Feb; 28(2):173-5. PubMed ID: 18250035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay.
    Kim GG; Donnenberg VS; Donnenberg AD; Gooding W; Whiteside TL
    J Immunol Methods; 2007 Aug; 325(1-2):51-66. PubMed ID: 17617419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.
    Kim HP; Gerhard B; Harasym TO; Mayer LD; Hogge DE
    Exp Hematol; 2011 Jul; 39(7):741-50. PubMed ID: 21530609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FISH+CD34+CD38- cells detected in newly diagnosed acute myeloid leukemia patients can predict the clinical outcome.
    Wang L; Gao L; Xu S; Gong S; Chen L; Lü S; Chen J; Qiu H; Xu X; Ni X; Song X; Zhang W; Yang J; Liu M; Hu X; Wang J
    J Hematol Oncol; 2013 Nov; 6(1):85. PubMed ID: 24517186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity.
    Schmohl JU; Felices M; Oh F; Lenvik AJ; Lebeau AM; Panyam J; Miller JS; Vallera DA
    Cancer Res Treat; 2017 Oct; 49(4):1140-1152. PubMed ID: 28231426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychoneuroimmunology and Natural Killer Cells: The Chromium-Release Whole-Blood Assay.
    Fletcher MA; Barnes Z; Broderick G; Klimas NG
    Methods Mol Biol; 2018; 1781():209-220. PubMed ID: 29705850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance against natural killer cell cytotoxicity: analysis of mechanisms.
    Hasenkamp J; Borgerding A; Wulf G; Uhrberg M; Jung W; Dingeldein S; Truemper L; Glass B
    Scand J Immunol; 2006 Oct; 64(4):444-9. PubMed ID: 16970688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel five-colour flow cytometric assay to determine NK cell cytotoxicity against neuroblastoma and other adherent tumour cells.
    Klöss S; Bochennek K; Huenecke S; Zimmermann SY; Kuçi S; Müller T; Wels WS; Klingebiel T; Esser R; Koehl U
    J Immunol Methods; 2007 Aug; 325(1-2):140-7. PubMed ID: 17663991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A real-time digital bio-imaging system to quantify cellular cytotoxicity as an alternative to the standard chromium-51 release assay.
    Fassy J; Tsalkitzi K; Salavagione E; Hamouda-Tekaya N; Braud VM
    Immunology; 2017 Apr; 150(4):489-494. PubMed ID: 28004383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of a flow cytometric assay for the determination of natural killer and cytotoxic T-lymphocyte activity in human and in different animal species.
    Piriou L; Chilmonczyk S; Genetet N; Albina E
    Cytometry; 2000 Dec; 41(4):289-97. PubMed ID: 11084614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of NK activity by the microcytotoxicity assay (MCA): a new application for an old assay.
    Wahlberg BJ; Burholt DR; Kornblith P; Richards TJ; Bruffsky A; Herberman RB; Vujanovic NL
    J Immunol Methods; 2001 Jul; 253(1-2):69-81. PubMed ID: 11384670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities.
    Costello RT; Mallet F; Gaugler B; Sainty D; Arnoulet C; Gastaut JA; Olive D
    Cancer Res; 2000 Aug; 60(16):4403-11. PubMed ID: 10969785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.